The global hub for new drug development, the first "H+A" stock, BioAtla successfully listed on the STAR Market
On December 10, Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd. (Biocytogen,$Biocytogen(688796.CN)) successfully listed on the STAR Market of the Shanghai Stock Exchange. This marks a crucial step for Biocytogen in deepening its capital market layout and enhancing corporate value following its listing on the Hong Kong Stock Exchange (02315.HK) on September 1, 2022, signifying the company's successful establishment of a dual-platform (H+A) listing structure.
The company's issue price was RMB 26.68 per share, with an opening price of RMB 58, representing a 117% increase from the issue price. At the opening price, the company's market capitalization exceeded RMB 25.9 billion.
Biocytogen Rings the Bell for Listing
Biocytogen is an international biotechnology company driven by innovative technologies for drug discovery. Addressing two major industry pain points—"obtaining high-quality source antibody molecules" and "achieving high-translation in vivo validation"—the company has built a globally leading "dual-engine platform" system. On one hand, through one of the most humanized antibody gene mouse platforms globally, the RenMice® Fully Human Antibody Platform, it has established a "Thousand Mice Ten Thousand Antibodies" resource library covering over 1,000 potentially druggable targets and more than one million authentic fully human antibody sequences, providing pharmaceutical companies with high-certainty, high-druggability source molecules. On the other hand, leveraging its globally leading target-humanized mouse repository, it offers thousands of high-precision, multi-disease in vivo validation models and services for efficacy, safety, and mechanism studies of various innovative therapies, including bispecific antibodies, ADCs, and nucleic acid drugs. Supported by the "Fully Human Antibody Library + Target-Humanized Mouse Library" dual-business system, the company has become a key partner for global multinational pharmaceutical firms, continuously driving the rapid translation of new targets, mechanisms, and cutting-edge therapies, and advancing the industry toward a higher-certainty era of drug development.
The successful A-share listing marks a new starting point for Biocytogen in technology platform transformation, global market expansion, and capital strategy synergy. The company will leverage the "A+H" collaborative advantage to further deepen diversified cooperation with global pharmaceutical firms, adhere to its original aspiration of "becoming the birthplace of global new drugs," strengthen technological barriers, and continuously consolidate its industry-leading position in innovative drug development, contributing to the high-quality development of the biopharmaceutical industry and enhancing China's global influence in the biopharmaceutical field.
Source: Biocytogen
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
